1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Clinical Trials: Building Quality At The Start Means Reducing Errors That Matter

 
• By Sue Sutter

Despite encouragement from regulators, quality-by-design and risk-based monitoring approaches for clinical trials have not been fully adopted. Experts say careful, cross-disciplinary thinking is needed in the study design phase, along with adoption of the quality mentality seen on the manufacturing side.  

Young plant
Quality should be built into clinical trials from the start. • Source: Shutterstock (Shutterstock)

Building quality into clinical trials up-front requires careful, cross-disciplinary thinking during the design phase about the most important risks to a study and adoption of the type of quality mindset that guides pharmaceutical manufacturing, experts said.

Key Takeaways

  • US and international regulators are encouraging incorporation of quality-by-design and risk-based monitoring approaches into clinical trials, but a risk-averse industry has been slow to embrace them outside the COVID-19 pandemic.

Regulators, industry representatives, clinical trial experts and patient advocacy groups discussed successes and challenges in integrating quality-by-design (QbD) and risk-based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Post-Approval, Real-Time Monitoring Will Help Approval Standards, US FDA’s Makary Says

 
• By Sue Sutter

The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.

EU Tests Unified Pathway For Combined Drug/IVD Studies

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By Vibha Sharma

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

More from R&D

Elevidys Helps Sarepta To First US FDA Platform Technology Designation

 
• By Bridget Silverman

Sarepta's rAAVrh74 vector, used in the marketed Duchenne muscular dystrophy gene therapy Elevidys and across the company's limb girdle muscular dystrophy pipeline, earned a platform designation as the lead LGMD candidate prepares for BLA filing.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By Vibha Sharma

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.